Home/Filings/4/0000911916-17-000076
4//SEC Filing

CoLucid Pharmaceuticals, Inc. 4

Accession 0000911916-17-000076

CIK 0001348649operating

Filed

Feb 28, 7:00 PM ET

Accepted

Mar 1, 12:20 PM ET

Size

18.9 KB

Accession

0000911916-17-000076

Insider Transaction Report

Form 4
Period: 2017-03-01
Marengere Luc
Director10% Owner
Transactions
  • Disposition from Tender

    Common Stock

    2017-03-01$46.50/sh1,545,386$71,860,4490 total(indirect: By TVM Life Science Ventures VII L.P.)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$36.50/sh5,954$217,3210 total
    Exercise: $10.00Exp: 2025-05-05Common Stock (5,954 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$40.26/sh8,897$358,1930 total
    Exercise: $6.24Exp: 2026-05-10Common Stock (8,897 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$38.00/sh1,449$55,0620 total
    Exercise: $8.50Exp: 2026-01-04Common Stock (1,449 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$36.88/sh2,371$87,4420 total
    Exercise: $9.62Exp: 2026-07-01Common Stock (2,371 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$10.30/sh658$6,7770 total
    Exercise: $36.20Exp: 2027-01-03Common Stock (658 underlying)
Transactions
  • Disposition from Tender

    Common Stock

    2017-03-01$46.50/sh1,545,386$71,860,4490 total(indirect: By TVM Life Science Ventures VII L.P.)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$36.88/sh2,371$87,4420 total
    Exercise: $9.62Exp: 2026-07-01Common Stock (2,371 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$10.30/sh658$6,7770 total
    Exercise: $36.20Exp: 2027-01-03Common Stock (658 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$36.50/sh5,954$217,3210 total
    Exercise: $10.00Exp: 2025-05-05Common Stock (5,954 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$38.00/sh1,449$55,0620 total
    Exercise: $8.50Exp: 2026-01-04Common Stock (1,449 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2017-03-01$40.26/sh8,897$358,1930 total
    Exercise: $6.24Exp: 2026-05-10Common Stock (8,897 underlying)
Footnotes (4)
  • [F1]Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest.
  • [F2]Represents securities held directly by TVM Life Science Ventures VII L.P. TVM Life Science Ventures VII (GP) Ltd. is the general partner of TVM Life Science Ventures VII L.P. The reporting person is a managing partner of the investment team of TVM Life Science Venture Capital, which has voting and investment power with respect to these shares. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  • [F3]Pursuant to the terms of the Merger Agreement, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
  • [F4]Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.

Issuer

CoLucid Pharmaceuticals, Inc.

CIK 0001348649

Entity typeoperating

Related Parties

1
  • filerCIK 0001348649

Filing Metadata

Form type
4
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 12:20 PM ET
Size
18.9 KB